Gland Pharma Management Guidance Tracker

Management expects steady sequential growth in U.S. revenue, with no decline anticipated.

Enoxaparin sales are expected to pick up from next quarter as inventory rationalization ends.

CFO guided that Cenexi's normalized quarterly revenue should be around EUR 50-55 million on a full quarter basis.

New programs in tech transfer and approval stages are expected to add EUR 30-40 million to Cenexi's annual revenue in the medium term.

Cenexi's quarterly revenue is expected to gradually increase from EUR 40M to EUR 50M in about three quarters.

Management expects base business (ex-Cenexi) to grow in mid-teens for the full fiscal year.

Cenexi expects revenue to exceed EUR 200 million in the next fiscal year, driving positive EBITDA.

Management expects full-year revenue growth in low double-digits, driven by new launches, Saudi recovery, and steady U.S. base business.

Management targets Cenexi quarterly revenue above EUR 15 million to support EBITDA breakeven, driven by new high-speed lines.

Management expects consolidated revenue to grow in the mid-teens percentage range in FY26, driven by new launches, CMO projects, and biologics.

The biologics segment, including the Dr. Reddy's collaboration, is expected to contribute approximately INR 100 crore in revenue in FY26.

Management reiterated guidance for mid-teen consolidated revenue growth for the full year, driven by U.S. launches and Cenexi recovery.

Management reaffirmed mid-teens revenue growth guidance for FY26, driven by new launches (dalbavancin, colistimethate) and Cenexi improvement.

Management expects base business to grow 12-13% in FY27, with potential upside from European CMS approvals and Dalbavancin launch.

Cenexi expected to maintain EUR 50 million quarterly run-rate on an annualized basis, with positive EBITDA trajectory.

Management expects 12-13% revenue growth in FY27 on constant currency basis, excluding GLP-1 upside.

Cenexi EBITDA margins are expected to improve in the next 1-2 quarters through operational efficiencies.

Management expects base business EBITDA margins to remain in the 30-32% range, with potential slight decline as lower-margin Enoxaparin supplies resume.

Management expects Cenexi to achieve EBITDA breakeven within 12-15 months, with medium-term EBITDA margin target of 10%.

Cenexi targets high-teen EBITDA margins within 1-2 years through operational fixes, tech transfers, and capacity expansion.

Management guided base business EBITDA margin in the range of 30-33% for the full year.

Cenexi is expected to achieve positive EBITDA by the fourth quarter of this fiscal year.

Cenexi targets positive EBITDA in Q4 FY25, supported by new ampoule line commercial production starting January 2025.

Cenexi aims for EBITDA breakeven in FY26, driven by revenue above EUR 200 million threshold.

Cenexi is expected to achieve positive EBITDA by Q3 FY26, delayed from earlier Q4 FY25 guidance due to ANSM inspection impact.

Cenexi is targeting to achieve positive EBITDA by the third quarter of FY26, with double-digit EBITDA margins expected in FY27.

Management expects Cenexi to deliver positive EBITDA in Q3 FY26, with Q2 being lower due to summer shutdown.

Cenexi is expected to break even in Q3 FY26, supported by EUR 50 million quarterly revenue target and cost initiatives.

Cenexi EBITDA losses reduced to EUR 5 million in H1 from EUR 11 million last year; management expects continued improvement.

Cenexi targets mid-single to high-single digit EBITDA margin for FY27, improving from current positive EBITDA.

Cenexi aims for mid-teen EBITDA margin in the medium term, driven by capacity additions and operational efficiencies.

Total product launches in FY24 will be higher than normal due to relaunches, exceeding 40.

Management expects steady quarter-on-quarter growth in the base business, driven by new launches and volume expansion.

Ex-Cenexi business targets mid-teens revenue growth over the next 2-3 years, driven by US complex products and CDMO opportunities.

Management expects the base business (ex-Cenexi) to grow at 14-15% annually, driven by new launches and market share gains.

The Dr. Reddy's biologics CDMO collaboration is expected to generate initial financial benefits from Q1 FY26.

Collaboration with Dr. Reddy's for biologics CDMO is expected to generate incremental revenue starting next financial year (FY26).

Management expects to commercialize around 20 million pens/cartridges in FY27, primarily for RoW markets.

Company targets 15% organic CAGR over five years, excluding inorganic contributions, driven by capacity expansions and CDMO contracts.

Planned investment of EUR 60 million in CapEx and working capital to enhance capacity and operational efficiencies at Cenexi.

Cenexi will invest approximately EUR 30 million in new equipment and capacity expansion over the next year.

Planned expansion of biologics drug substance capacity by 15KL to support the Shanghai Henlius collaboration, with revenue likely from FY27-28.

Gland is adding 100 million units of cartridge capacity, reaching 140 million units total by calendar year 2026, to support GLP-1 contracts.

The new 100 million cartridge line will be ready for commercialization by March 2026, adding to the existing 40 million capacity.

Expected CapEx for Gland base business is approximately INR 2,500 million for FY26, focused on capacity expansion.

Brownfield expansions include BFS, ophthalmic lines, and CDMO-dedicated capacity; FY27 CapEx expected >INR 400 crore.

Capital expenditure for FY27 expected to be around INR 500 crores, part of INR 2,000 crores over five years.